Myriad Genetics unveils Prolaris Plus AI test to support prostate cancer surveillance decisions

Myriad Genetics unveils Prolaris Plus AI test to support prostate cancer surveillance decisions
Myriad Genetics unveils AI prostate test

Myriad Genetics has announced the introduction of the Prolaris Plus AI Prostate Cancer Prognostic Test during an upcoming educational webinar.

The new AI-powered enhancement is designed to provide clinicians and patients with deeper insights to guide active surveillance decisions for prostate cancer. The company aims to advance personalized medicine in oncology by utilizing artificial intelligence to refine prognosis. Registration for the webinar event is open to those interested in learning more about the technology.

Myriad Genetics previously unveiled an AI-enhanced test for active surveillance aimed at improving management in urology and prostate cancer care. The company has also announced plans to combine molecular scores and AI digital pathology with the Prolaris Plus AI test for prostate cancer diagnosis. Both initiatives reflect Myriad Genetics’ ongoing focus on incorporating artificial intelligence into clinical decision-making.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.